kynurenic acid has been researched along with Alzheimer Disease in 24 studies
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.
kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, reduces the clinical deterioration in moderate-to-severe Alzheimer disease (AD) for which other treatments are not available." | 3.72 | Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. ( Grundke-Iqbal, I; Haque, N; Iqbal, K; Li, L; Sengupta, A, 2004) |
| "Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach." | 2.82 | Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword? ( Ostapiuk, A; Urbanska, EM, 2022) |
| "Kynurenic acid (KYNA) is an endogenous antagonist of NMDA receptors which has been demonstrated under experimental conditions to be neuroprotective." | 2.53 | Memantine and Kynurenic Acid: Current Neuropharmacological Aspects. ( Majláth, Z; Toldi, J; Török, N; Vécsei, L, 2016) |
| "Kynurenic acid (KYNA) is a potential biomarker candidate for this purpose." | 1.62 | Kynurenic Acid Electrochemical Immunosensor: Blood-Based Diagnosis of Alzheimer's Disease. ( Marco, MP; Marrugo-Ramírez, J; Mir, M; Rodríguez-Núñez, M; Samitier, J, 2021) |
| "elegans model of Alzheimer's disease." | 1.62 | Two human metabolites rescue a C. elegans model of Alzheimer's disease via a cytosolic unfolded protein response. ( Casford, S; Chia, S; Dobson, CM; Habchi, J; Joshi, P; Labbadia, J; Limbocker, R; Mannini, B; Perni, M; Vendruscolo, M, 2021) |
| "Kynurenic acid (KYNA) is a product of the tryptophan (TRP) metabolism via the kynurenine pathway (KP)." | 1.56 | Kynurenic Acid Levels are Increased in the CSF of Alzheimer's Disease Patients. ( Antequera, D; Arjona, JAM; Bartolome, F; Bisa, AL; Carro, E; Domínguez, E; González-Sánchez, M; Jiménez, J; Llamas-Velasco, S; Marco, MP; Martín, AH; Munain, AL; Narváez, A; Pérez-Martínez, DA; Rodríguez-Núñez, M; Villarejo-Galende, A, 2020) |
| "However, in Alzheimer's disease (AD), NSCs lose plasticity and thus possible regenerative capacity." | 1.48 | 3D Culture Method for Alzheimer's Disease Modeling Reveals Interleukin-4 Rescues Aβ42-Induced Loss of Human Neural Stem Cell Plasticity. ( Antos, CL; Bhattarai, P; Brandt, K; Bray, L; Celikkaya, H; Chen, X; Cosacak, MI; Dahl, A; Freudenberg, U; Friedrichs, J; He, S; Hollak, H; Kizil, C; Kurth, T; Lin, W; Mashkaryan, V; Papadimitriou, C; Thomas, AK; Werner, C; Zhang, Y, 2018) |
| "In a transgenic mouse model of Alzheimer's disease, JM6 prevents spatial memory deficits, anxiety-related behavior, and synaptic loss." | 1.37 | Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. ( Adame, A; Andrews-Zwilling, Y; Flik, G; Giorgini, F; Guidetti, P; Hsieh, EW; Huang, SY; Huang, Y; Laue, G; Lee, J; Louie, JY; Masliah, E; Moussaoui, S; Muchowski, JM; Muchowski, PJ; Notarangelo, FM; Patrick, C; Rassoulpour, A; Sathyasaikumar, KV; Scearce-Levie, K; Schwarcz, R; Truong, J; Wu, HQ; Wu, T; Zwilling, D, 2011) |
| "The kynurenine pathway (KP) is a major route of tryptophan metabolism." | 1.36 | Kynurenine and its metabolites in Alzheimer's disease patients. ( Bien, B; Gulaj, E; Pawlak, D; Pawlak, K, 2010) |
| "Galantamine, a drug used to treat Alzheimer's disease, is a nicotinic allosteric potentiating ligand, and kynurenic acid (KYNA), a neuroactive metabolite of the kynurenine pathway, is an endogenous noncompetitive inhibitor of alpha7* nicotinic receptors (nAChRs) [the asterisk next to the nAChR subunit is intended to indicate that the exact subunit composition of the receptor is not known (Pharmacol Rev 51:397-401, 1999)]." | 1.34 | Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors. ( Albuquerque, EX; Lopes, C; Njar, V; Pereira, EF; Purushottamachar, P; Schwarcz, R; Wu, HQ, 2007) |
| "L-kynurenine (L-KYN) serves as a substrate for the synthesis of neurotoxic 3-OH-kynurenine (3-OH-KYN) and neuroprotective kynurenic acid (KYNA)." | 1.30 | Kynurenine metabolism in Alzheimer's disease. ( Baran, H; Deecke, L; Jellinger, K, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 4 (16.67) | 29.6817 |
| 2010's | 9 (37.50) | 24.3611 |
| 2020's | 9 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Siddiqui, T | 1 |
| Bhattarai, P | 2 |
| Popova, S | 1 |
| Cosacak, MI | 2 |
| Sariya, S | 1 |
| Zhang, Y | 2 |
| Mayeux, R | 1 |
| Tosto, G | 1 |
| Kizil, C | 2 |
| Ostapiuk, A | 1 |
| Urbanska, EM | 1 |
| Almulla, AF | 1 |
| Supasitthumrong, T | 1 |
| Amrapala, A | 1 |
| Tunvirachaisakul, C | 1 |
| Jaleel, AKA | 1 |
| Oxenkrug, G | 1 |
| Al-Hakeim, HK | 1 |
| Maes, M | 1 |
| Fathi, M | 1 |
| Vakili, K | 1 |
| Yaghoobpoor, S | 1 |
| Tavasol, A | 1 |
| Jazi, K | 1 |
| Hajibeygi, R | 1 |
| Shool, S | 1 |
| Sodeifian, F | 1 |
| Klegeris, A | 1 |
| McElhinney, A | 1 |
| Tavirani, MR | 1 |
| Sayehmiri, F | 1 |
| González-Sánchez, M | 1 |
| Jiménez, J | 1 |
| Narváez, A | 1 |
| Antequera, D | 1 |
| Llamas-Velasco, S | 1 |
| Martín, AH | 1 |
| Arjona, JAM | 1 |
| Munain, AL | 1 |
| Bisa, AL | 1 |
| Marco, MP | 2 |
| Rodríguez-Núñez, M | 2 |
| Pérez-Martínez, DA | 1 |
| Villarejo-Galende, A | 1 |
| Bartolome, F | 1 |
| Domínguez, E | 1 |
| Carro, E | 1 |
| Maitre, M | 1 |
| Klein, C | 1 |
| Patte-Mensah, C | 1 |
| Mensah-Nyagan, AG | 1 |
| Marrugo-Ramírez, J | 1 |
| Mir, M | 1 |
| Samitier, J | 1 |
| van der Velpen, V | 1 |
| Rosenberg, N | 1 |
| Maillard, V | 1 |
| Teav, T | 1 |
| Chatton, JY | 1 |
| Gallart-Ayala, H | 1 |
| Ivanisevic, J | 1 |
| Joshi, P | 1 |
| Perni, M | 1 |
| Limbocker, R | 1 |
| Mannini, B | 1 |
| Casford, S | 1 |
| Chia, S | 1 |
| Habchi, J | 1 |
| Labbadia, J | 1 |
| Dobson, CM | 1 |
| Vendruscolo, M | 1 |
| Deora, GS | 1 |
| Kantham, S | 1 |
| Chan, S | 1 |
| Dighe, SN | 1 |
| Veliyath, SK | 1 |
| McColl, G | 1 |
| Parat, MO | 1 |
| McGeary, RP | 1 |
| Ross, BP | 1 |
| Papadimitriou, C | 1 |
| Celikkaya, H | 1 |
| Mashkaryan, V | 1 |
| Bray, L | 1 |
| Brandt, K | 1 |
| Hollak, H | 1 |
| Chen, X | 1 |
| He, S | 1 |
| Antos, CL | 1 |
| Lin, W | 1 |
| Thomas, AK | 1 |
| Dahl, A | 1 |
| Kurth, T | 1 |
| Friedrichs, J | 1 |
| Freudenberg, U | 1 |
| Werner, C | 1 |
| Sharma, R | 1 |
| Razdan, K | 1 |
| Bansal, Y | 1 |
| Kuhad, A | 1 |
| Majláth, Z | 1 |
| Török, N | 1 |
| Toldi, J | 1 |
| Vécsei, L | 1 |
| Gulaj, E | 1 |
| Pawlak, K | 1 |
| Bien, B | 1 |
| Pawlak, D | 1 |
| Zwilling, D | 1 |
| Huang, SY | 1 |
| Sathyasaikumar, KV | 1 |
| Notarangelo, FM | 1 |
| Guidetti, P | 1 |
| Wu, HQ | 2 |
| Lee, J | 1 |
| Truong, J | 1 |
| Andrews-Zwilling, Y | 1 |
| Hsieh, EW | 1 |
| Louie, JY | 1 |
| Wu, T | 1 |
| Scearce-Levie, K | 1 |
| Patrick, C | 1 |
| Adame, A | 1 |
| Giorgini, F | 1 |
| Moussaoui, S | 1 |
| Laue, G | 1 |
| Rassoulpour, A | 1 |
| Flik, G | 1 |
| Huang, Y | 1 |
| Muchowski, JM | 1 |
| Masliah, E | 1 |
| Schwarcz, R | 2 |
| Muchowski, PJ | 1 |
| Gong, CY | 1 |
| Li, Z | 1 |
| Wang, HM | 1 |
| Liu, J | 1 |
| Chen, L | 1 |
| Zhang, HW | 1 |
| Wang, X | 1 |
| Yang, J | 1 |
| Tan, L | 2 |
| Yu, JT | 1 |
| Schwarz, MJ | 1 |
| Guillemin, GJ | 1 |
| Teipel, SJ | 1 |
| Buerger, K | 1 |
| Hampel, H | 1 |
| Li, L | 1 |
| Sengupta, A | 1 |
| Haque, N | 1 |
| Grundke-Iqbal, I | 1 |
| Iqbal, K | 1 |
| Hartai, Z | 1 |
| Juhász, A | 1 |
| Rimanóczy, A | 1 |
| Janáky, T | 1 |
| Donkó, T | 1 |
| Dux, L | 1 |
| Penke, B | 1 |
| Tóth, GK | 1 |
| Janka, Z | 1 |
| Kálmán, J | 1 |
| Lopes, C | 1 |
| Pereira, EF | 1 |
| Purushottamachar, P | 1 |
| Njar, V | 1 |
| Albuquerque, EX | 1 |
| Baran, H | 1 |
| Jellinger, K | 1 |
| Deecke, L | 1 |
| Fitzjohn, SM | 1 |
| Morton, RA | 1 |
| Kuenzi, F | 1 |
| Rosahl, TW | 1 |
| Shearman, M | 1 |
| Lewis, H | 1 |
| Smith, D | 1 |
| Reynolds, DS | 1 |
| Davies, CH | 1 |
| Collingridge, GL | 1 |
| Seabrook, GR | 1 |
| Beal, MF | 1 |
| Matson, WR | 1 |
| Storey, E | 1 |
| Milbury, P | 1 |
| Ryan, EA | 1 |
| Ogawa, T | 1 |
| Bird, ED | 1 |
7 reviews available for kynurenic acid and Alzheimer Disease
| Article | Year |
|---|---|
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Huntington Disease; Ky | 2022 |
The Tryptophan Catabolite or Kynurenine Pathway in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Topics: Aged; Alzheimer Disease; Brain; Humans; Kynurenic Acid; Kynurenine; Tryptophan | 2022 |
Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Topics: 3-Hydroxyanthranilic Acid; Adenosine; Alzheimer Disease; Humans; Huntington Disease; Hydroxyindoleac | 2022 |
Tryptophan metabolites modify brain Aβ peptide degradation: A role in Alzheimer's disease?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Humans; Hydroxyindoleacetic Acid; Kynurenic Acid; Neprilys | 2020 |
Rollercoaster ride of kynurenines: steering the wheel towards neuroprotection in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cognitive Dysfunction; Drug Development; Humans; Kynurenic Acid; Kynuren | 2018 |
Memantine and Kynurenic Acid: Current Neuropharmacological Aspects.
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Kynurenic Acid; Memant | 2016 |
The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Enzyme Inhibitors; Humans; Hunting | 2012 |
17 other studies available for kynurenic acid and Alzheimer Disease
| Article | Year |
|---|---|
KYNA/Ahr Signaling Suppresses Neural Stem Cell Plasticity and Neurogenesis in Adult Zebrafish Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Brain; Cell Proliferation; Cohort Studies; Disease Models, Animal; Human | 2021 |
Kynurenic Acid Levels are Increased in the CSF of Alzheimer's Disease Patients.
Topics: Aged; Alzheimer Disease; Case-Control Studies; Female; Humans; Kynurenic Acid; Male; Middle Aged; Tr | 2020 |
Kynurenic Acid Electrochemical Immunosensor: Blood-Based Diagnosis of Alzheimer's Disease.
Topics: Alzheimer Disease; Biomarkers; Biosensing Techniques; Dielectric Spectroscopy; Early Diagnosis; Elec | 2021 |
Sex-specific alterations in NAD+ metabolism in 3xTg Alzheimer's disease mouse brain assessed by quantitative targeted LC-MS.
Topics: Alzheimer Disease; Animals; Chromatography, High Pressure Liquid; Encephalitis; Female; Humans; Kynu | 2021 |
Two human metabolites rescue a C. elegans model of Alzheimer's disease via a cytosolic unfolded protein response.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Caenorhabditis elegans; Caenorhabditis elegans Pr | 2021 |
Multifunctional Analogs of Kynurenic Acid for the Treatment of Alzheimer's Disease: Synthesis, Pharmacology, and Molecular Modeling Studies.
Topics: Alzheimer Disease; Animals; Binding Sites; Caenorhabditis elegans; Dose-Response Relationship, Drug; | 2017 |
3D Culture Method for Alzheimer's Disease Modeling Reveals Interleukin-4 Rescues Aβ42-Induced Loss of Human Neural Stem Cell Plasticity.
Topics: Adult; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cell Plasticity; | 2018 |
Kynurenine and its metabolites in Alzheimer's disease patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chromatography, High Pressure Liquid; Female; Humans; Ky | 2010 |
Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration.
Topics: Administration, Oral; Alzheimer Disease; Animals; Brain Chemistry; Disease Models, Animal; Female; H | 2011 |
Targeting the kynurenine pathway as a potential strategy to prevent and treat Alzheimer's disease.
Topics: Alzheimer Disease; Humans; Inflammation; Kynurenic Acid; Models, Biological; Quinolinic Acid; Recept | 2011 |
Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls.
Topics: Aged; Alzheimer Disease; Biomarkers; Blood-Brain Barrier; Brain Chemistry; Chromatography, High Pres | 2013 |
Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration.
Topics: 2-Amino-5-phosphonovalerate; Alzheimer Disease; Animals; Calcium-Calmodulin-Dependent Protein Kinase | 2004 |
Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Erythrocytes; Female; Genoty | 2007 |
Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors.
Topics: Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Animals; Atropine | 2007 |
Kynurenine metabolism in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Caudate Nucleus; Female; Humans; Kinetics; Kynure | 1999 |
Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Disease Models, Animal; Electric | 2001 |
Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex.
Topics: Aged; Alzheimer Disease; Cerebral Cortex; Energy Metabolism; Free Radicals; Humans; Huntington Disea | 1992 |